Compare TY & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | BCRX |
|---|---|---|
| Founded | 1929 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 1994 |
| Metric | TY | BCRX |
|---|---|---|
| Price | $33.36 | $6.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 43.0K | ★ 4.7M |
| Earning Date | 01-01-0001 | 02-23-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | ★ $599,816,000.00 |
| Revenue This Year | N/A | $39.83 |
| Revenue Next Year | N/A | $5.47 |
| P/E Ratio | $6.38 | ★ N/A |
| Revenue Growth | N/A | ★ 45.38 |
| 52 Week Low | $25.16 | $6.00 |
| 52 Week High | $30.73 | $11.31 |
| Indicator | TY | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 40.45 |
| Support Level | $32.53 | $6.46 |
| Resistance Level | $33.54 | $7.15 |
| Average True Range (ATR) | 0.28 | 0.39 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 81.68 | 16.67 |
Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.